<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="395">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611802</url>
  </required_header>
  <id_info>
    <org_study_id>2019nCoV-301</org_study_id>
    <nct_id>NCT04611802</nct_id>
  </id_info>
  <brief_title>A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2</brief_title>
  <official_title>A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effectiveness, immune response, and safety of a coronavirus&#xD;
      disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults 18&#xD;
      years of age and older in the United States and Mexico. A vaccine causes the body to have an&#xD;
      immune response that may help prevent the infection or reduce the severity of symptoms. An&#xD;
      adjuvant is something that can make a vaccine work better. This study will look at the&#xD;
      protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1&#xD;
      adjuvant in the study population. Participants in the study will randomly be assigned to&#xD;
      receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will&#xD;
      receive a total of 2 intramuscular injections of either ARS-CoV-2 rS with Matrix-M1 adjuvant&#xD;
      or placebo in Initial Vaccination Period. Up to 30,000 participants will take part in the&#xD;
      study. Following authorization for Emergency Use in the US based on demonstration of&#xD;
      statistically significant vaccine efficacy and satisfactory safety in an analysis of the&#xD;
      primary endpoint sufficient to support application for EUA, participants will be scheduled&#xD;
      for administration of 2 injections of the alternate study material 21 days apart (&quot;blinded&#xD;
      crossover&quot;). That is, initial recipients of placebo will receive SARS-CoV-2 rS with Matrix-M1&#xD;
      adjuvant and initial recipients of SARS-CoV-2 rS with Matrix-M1 adjuvant will receive&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To obtain contact information for a study center near you, please visit:&#xD;
&#xD;
      https://www.novavax.com/PREVENT-19?utm_source=ctgov&amp;utm_medium=link&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)</measure>
    <time_frame>Day 28 to Day 750</time_frame>
    <description>Number of participants with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with Symptomatic Moderate or Severe COVID-19</measure>
    <time_frame>Day 28 to Day 750</time_frame>
    <description>Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic moderate or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with Any Symptomatic COVID-19</measure>
    <time_frame>Day 28 to Day 750</time_frame>
    <description>Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with any symptomatic COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs)</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs)</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Neutralizing antibody activity as detected by MN as expressed as GMFRs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG Antibody Levels Expressed as GMFRs</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs</measure>
    <time_frame>Day 0 to Day 105</time_frame>
    <description>Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Days 0, 35 and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Activity Expressed as GMTs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Neutralizing antibody activity as detected by MN as expressed as GMTs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points</measure>
    <time_frame>Day 165 to Day 750</time_frame>
    <description>Neutralizing antibody activity as detected by MN as expressed as GMFRs at Months 6, 12, 18, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Course, Treatment and Severity of COVID-19</measure>
    <time_frame>Day 28 to Day 750</time_frame>
    <description>Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case via the Endpoint Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity Incidence and Severity</measure>
    <time_frame>Day 0 to Day 27</time_frame>
    <description>Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49</measure>
    <time_frame>Day 0 to Day 49</time_frame>
    <description>Number of participants with mild, moderate, or severe MAAEs through Day 49.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49</measure>
    <time_frame>Day 0 to Day 49</time_frame>
    <description>Number of participants with mild, moderate, or severe AEs through Day 49.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12</measure>
    <time_frame>Day 0 to Day 375</time_frame>
    <description>Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12</measure>
    <time_frame>Day 0 to Day 375</time_frame>
    <description>Number of participants with mild, moderate, or severe SAEs through Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12</measure>
    <time_frame>Day 0 to Day 375</time_frame>
    <description>Number of participants with mild, moderate, or severe AESIs through Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of SAEs from Month 12 to Month 24</measure>
    <time_frame>Day 360 to Day 750</time_frame>
    <description>Number of participants with mild, moderate, or severe SAEs from Month 12 to Month 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24</measure>
    <time_frame>Day 360 to Day 750</time_frame>
    <description>Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine from Month 12 to Month 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of AESIs from Month 12 to Month 24</measure>
    <time_frame>Day 360 to Day 750</time_frame>
    <description>Number of participants with mild, moderate, or severe AESIs attributed to study vaccine from Month 12 to Month 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths Due to Any Cause</measure>
    <time_frame>Day 0 to Day 750</time_frame>
    <description>Number of participants who died during the study due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points</measure>
    <time_frame>Day 0 to Day 750</time_frame>
    <description>Number of participants with antibodies to SARS-CoV-2 NP at Days 0 and 35, or Months 3, 6, 12, 18 and 24 to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point</measure>
    <time_frame>Day 0 to Day 750</time_frame>
    <description>Number of participants with antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG antibodies to SARS-CoV-2 rS at Day 35 After First Crossover Vaccination</measure>
    <time_frame>Day 35 after the first crossover vaccination</time_frame>
    <description>The ratio of geometric mean IgG antibody concentrations will be computed at Day 35 for the new manufacturing process versus the old manufacturing process using the data from the participants selected for analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 rS/Matrix-M1 Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period. One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)</intervention_name>
    <description>Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.</description>
    <arm_group_label>SARS-CoV-2 rS/Matrix-M1 Adjuvant</arm_group_label>
    <other_name>NVX-CoV2373</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Initial Vaccination Period)</intervention_name>
    <description>Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0.9% (BP, sterile)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)</intervention_name>
    <description>In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21</description>
    <arm_group_label>SARS-CoV-2 rS/Matrix-M1 Adjuvant</arm_group_label>
    <other_name>NVX-CoV2373</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Crossover Vaccination period)</intervention_name>
    <description>In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0.9% (BP, sterile)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age at screening who, by virtue of age, race, ethnicity or life&#xD;
             circumstances, are considered at substantial risk of exposure to and infection with&#xD;
             SARS-CoV-2.&#xD;
&#xD;
          -  Willing and able to give informed consent prior to study enrollment and to comply with&#xD;
             study procedures.&#xD;
&#xD;
          -  Participants of childbearing potential (defined as any participant who has experienced&#xD;
             menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least&#xD;
             12 consecutive months]) must agree to be heterosexually inactive from at least 28 days&#xD;
             prior to enrollment and through 3 months after the last vaccination OR agree to&#xD;
             consistently use a medically acceptable method of contraception from at least 28 days&#xD;
             prior to enrollment and through 3 months after the last vaccination.&#xD;
&#xD;
          -  Is medically stable, as determined by the investigator (based on review of health&#xD;
             status, vital signs [to include body temperature], medical history, and targeted&#xD;
             physical examination [to include body weight]). Vital signs must be within medically&#xD;
             acceptable ranges prior to the first vaccination.&#xD;
&#xD;
          -  Agree to not participate in any other SARS-CoV-2 prevention trial during the study&#xD;
             follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable acute or chronic illness. Criteria for unstable medical conditions include:&#xD;
&#xD;
               1. Substantive changes in chronic prescribed medication (change in class or&#xD;
                  significant change in dose) in the past 2 months.&#xD;
&#xD;
               2. Currently undergoing workup of undiagnosed illness that could lead to diagnosis&#xD;
                  of a new condition.&#xD;
&#xD;
          -  Participation in research involving an investigational product (drug/biologic/device)&#xD;
             within 45 days prior to first study vaccination.&#xD;
&#xD;
          -  History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or&#xD;
             COVID-19.&#xD;
&#xD;
          -  Received influenza vaccination or any other adult vaccine within 4 days prior to or&#xD;
             within 7 days after either study vaccination.&#xD;
&#xD;
          -  Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring&#xD;
             ongoing immunomodulatory therapy.&#xD;
&#xD;
          -  Chronic administration (defined as &gt; 14 continuous days) of immunosuppressant,&#xD;
             systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to&#xD;
             first study vaccination.&#xD;
&#xD;
          -  Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90&#xD;
             days prior to first study vaccination.&#xD;
&#xD;
          -  Active cancer (malignancy) on therapy within 1 year prior to first study vaccination&#xD;
             (with the exception of malignancy cured via excision, at the discretion of the&#xD;
             investigator).&#xD;
&#xD;
          -  Any known allergies to products contained in the investigational product.&#xD;
&#xD;
          -  Participants who are breastfeeding, pregnant or who plan to become pregnant within 3&#xD;
             months following last study vaccination.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, would pose a health risk&#xD;
             to the participant if enrolled or could interfere with evaluation of the trial vaccine&#xD;
             or interpretation of study results.&#xD;
&#xD;
          -  Study team member or first-degree relative of any study team member (inclusive of&#xD;
             Sponsor, and study site personnel involved in the study).&#xD;
&#xD;
          -  Current participation in any other COVID-19 prevention clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa M Dunkle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novavax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR Tempe Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Rancho Paseo</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite - Corporate Offices</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-Pri, Llc</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transitional Research Group, Inc.</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-2201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Health Medical Foundation - Woodland</name>
      <address>
        <city>Woodland</city>
        <state>California</state>
        <zip>95695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital Howard/ University College of Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research-Deland, LLC dba Accel Research Sites</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIMED Health, LLC / SIMED Research</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research/Accel Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Veterans Affairs Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jedidiah Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, Llc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta - Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce CRS Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health (DBA John B. Amos Cancer Center)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providea Health Partners LLC</name>
      <address>
        <city>Mokena</city>
        <state>Illinois</state>
        <zip>60448</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus USA</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buynak Clinical Research, P.C.</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Medical Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Pharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Physician Network</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Maryland School Of Medicine CVD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/ Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Richfield</city>
        <state>Minnesota</state>
        <zip>55423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC-Biloxi</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Curators of University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201-5276</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research Associates, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Responder Vaccine Program</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3-Emerging Medical Research, LLC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womack Army Medical Center</name>
      <address>
        <city>Fort Bragg</city>
        <state>North Carolina</state>
        <zip>28310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Rocky Mount, LLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research, US, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research International</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRISOR, LLC - Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital (TMH)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>09206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Providence</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, SCTR Research Nexus</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Breaks Industries Research Inc.</name>
      <address>
        <city>Eagle Butte</city>
        <state>South Dakota</state>
        <zip>57625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR Clinsearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research, Inc. d/b/a PMG Research of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Research Center at Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Your Health</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus, US - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research &amp; Innovation</name>
      <address>
        <city>Cheney</city>
        <state>Washington</state>
        <zip>99004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington VTEU</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research Mexico</name>
      <address>
        <city>Juriquilla</city>
        <state>Queretaro</state>
        <zip>76230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Atencion Medica e Investigacion en Salud (UNAMIS)</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Salud Publica (INSP) - Cuernavaca - Centro de Investigacion en Salud Poblacional (CISP)</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAIMED Investigacion en Salud S.A de C.V</name>
      <address>
        <city>Mexico City</city>
        <zip>6760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faicic S. de R.L. de C.V.</name>
      <address>
        <city>Veracruz</city>
        <zip>91900</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation Inc. / CAIMED Cneter</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico Medical Sciences Campus Maternal Infant Studies Center</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>Prevent-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

